Skip to main content
BMRN logo

BioMarin Pharmaceutical Inc. (BMRN) Stock: Price, Forecast & Analyst Target

BioMarin Pharmaceutical Inc. (BMRN) — MoonshotScore 58/100 (Fair band), calculated Nov 18, 2026. Price $61.43 (+4.99%), as of the Nov 18, 2026 trading session; market cap $11.9B. Expected results Feb 22, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 16.17× (cash as of Sep 30, 2026) · expected results Feb 22, 2027

$61.43 +$2.92 (+4.99%) Market Cap $11.9B

BioMarin Pharmaceutical Inc. · BMRN · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: BioMarin sells treatments for severe rare genetic and metabolic disorders, with an established commercial portfolio rather than a business resting mainly on clinical milestones. The case depends on whether newer portfolio additions and patient growth can lift revenue while earnings, operating expenses and liquidity settle into a more durable pattern.

Price as of Nov 18, 2026

Key Statistics

58 of 100

MoonshotScore v2 · BioMarin Pharmaceutical (BMRN)

Fair
Business Quality Solid (76)
Financial Safety Fragile (14)
Valuation Full (54)
Growth Durability Fading (30)
Momentum Rising (76)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a fragile balance sheet, weak growth and a full valuation; the market is already moving on it. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Fading; Momentum: Rising.

  • quarterly revenue $776M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 5 of the last 8 reports
  • Altman Z 1.91 · Piotroski F 2

Holding back: balance-sheet strain, soft growth

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BMRN (57 recorded, newest six shown)
RecordedScoreBand
61Fair
61Fair
61Fair
61Fair
58Fair
58Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$61.43
Change on the day+4.99%
52-week range$49.26–$70.98
Market capitalisation$11.9B—
Price / earnings (trailing)153.97
Shares traded on the day3.07M
Beta (volatility vs the S&P 500)0.23

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $51, high $67, latest $61. 4 reported quarters marked, 2 above and 2 below the recorded estimate. 1 other dated event marked. $67 $51 high $67 Feb 23, 2026 · Earnings results · reported below the recorded estimate · close $641May 4, 2026 · Earnings results · reported below the recorded estimate · close $542Aug 6, 2026 · Earnings results · reported above the recorded estimate · close $643Nov 2, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $594Nov 2, 2026 · Earnings results · reported above the recorded estimate · close $595 Oct 17, 2025 Nov 18, 2026 · $61 $53Oct 17, 2025$54Oct 31, 2025$55Nov 14, 2025$56Nov 28, 2025$53Dec 12, 2025$60Dec 26, 2025$59Jan 9, 2026$56Jan 23, 2026$58Feb 6, 2026$64Feb 20, 2026$61Mar 6, 2026$54Mar 20, 2026$56Apr 2, 2026$55Apr 17, 2026$54May 1, 2026$52May 15, 2026$57May 29, 2026$56Jun 12, 2026$59Jun 26, 2026$59Jul 10, 2026$59Jul 24, 2026$64Aug 7, 2026$67Aug 21, 2026$67Sep 4, 2026$64Sep 18, 2026$57Oct 2, 2026$55Oct 16, 2026$59Oct 30, 2026$57Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • More than 75% of revenue in the third quarter was generated outside of the U.S., and we expect this segment to be a leading area of expansion in achondroplasia.

    Cristin Hubbard · Statement from

  • And our updated guidance is based on timing of revenue between Q4 and next year.

    Brian R. Mueller · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for BioMarin Pharmaceutical (BMRN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Neutral
Growth Durability Weak
Momentum Moderate

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Moderate
Debt/Equity Weak
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is BioMarin Pharmaceutical (BMRN), and what does it report?

Short answer · as of

BioMarin earns nearly all of its revenue from medicines such as Vimizim, Naglazyme, Palynziq, Brineura and Voxzogo; royalties and other revenue are peripheral.

Demand reflects diagnosed and treated patients, new therapy starts, dose progression and purchasing schedules across specialty pharmacies, hospitals, government health bodies, distributors and wholesalers.

That commercial base makes BioMarin different from a clinical-stage biotechnology company whose value depends chiefly on trial outcomes. Research remains substantial, but the reported income statement already measures a global rare-disease franchise with meaningful product sales and positive annual earnings.

2 · Latest results

What do the latest results show for BioMarin Pharmaceutical (BMRN)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $776M.

The latest period delivered the strongest revenue in the reported quarterly series, positive operating and net income, and revenue and earnings above market expectations. Profit did not rise with sales, however: operating income and net income declined from the preceding period as research and administrative spending increased.

Management had previously expected purchasing schedules and fuller contributions from Galafold, Pombility and Opfolda to make the later part of the year stronger than the earlier part. That explanation identifies the commercial mechanism, but the expense pattern shows why revenue growth alone does not establish durable earnings growth.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$1.02B Sep 30, 2026
Latest quarter · R&D
$180.53M Sep 30, 2026
Latest quarter · SG&A
$333.64M Sep 30, 2026
Latest quarter · FMP standardized operating result
−$82.08M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$1.02B$180.53M$333.64M−$82.08M
Jun 30, 2026$989.71M$206.95M$395.54M$110.93M
Mar 31, 2026$766.21M$178.80M$258.30M$129.63M
Dec 31, 2025$874.57M$192.41M$802.12M$79.39M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.02B Nov 2, 2026
Latest report · revenue estimate
$1.02B Nov 2, 2026
Latest report · revenue vs estimate
In line Nov 2, 2026
Latest report · EPS vs estimate
Above estimate Nov 2, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 2, 2026$1.02B$1.02B$0.2300−$0.0493
Aug 6, 2026$989.71M$932.03M$1.2000$0.9470
May 4, 2026$766.00M$752.53M$0.7600$0.7800
Feb 23, 2026$874.57M$833.73M−$0.2400$0.1694
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$776M-$31M-$0.16 (diluted)
Q4 FY2025$875M-$47M-$0.22 (diluted)
Q1 FY2026$766M$106M$0.54 (diluted)
Q2 FY2026$990M$45M$0.23 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for BioMarin Pharmaceutical (BMRN)?

Short answer · as of

Cash and short-term investments were $736.01M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $188.21M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Operations have generated cash throughout the reported quarterly window, while capital spending has remained modest relative to operating inflows. High gross profitability also gives BioMarin room to fund research and commercialization, although recent swings in operating and net margins show that this room can be consumed quickly.

Debt substantially exceeds cash and investments, and the latest cash balance fell sharply from the preceding period. Near-term liquidity ratios remain supportive, but cash alone would cover only a limited portion of total debt; the broader quality and distress screens therefore sit alongside genuine cash generation rather than replacing scrutiny of leverage.

The business-specific financial risk is that patient starts, titration or order timing disappoint while research and commercial costs remain elevated. Because revenue is overwhelmingly product based, disruption across the marketed portfolio would reach cash generation more directly than weakness in the small royalty stream.

Data-derived red flags

  • Negative return on equity (-0.3%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
  • Rich valuation — a P/E of 153.97 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$188.21M Sep 30, 2026
Previous quarter · operating cash flow
$168.11M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$188.21M−$28.29M
Jun 30, 2026$168.11M−$28.82M
Mar 31, 2026$220.65M−$20.92M
Dec 31, 2025$99.64M−$40.72M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at BioMarin Pharmaceutical (BMRN)?

Short answer · as of

The next earnings report is expected on Feb 22, 2027.

Watch whether Galafold, Pombility and Opfolda provide the fuller contribution management anticipated, whether enzyme therapies sustain growth, and whether Palynziq gains from new patient starts and progression toward maintenance dosing. These observations test management's stated revenue mechanism rather than merely comparing the result with consensus.

The accompanying financial checks are whether operating profit keeps pace with revenue, operating cash flow remains positive and the cash balance stabilizes after its recent drop. Longer-range market estimates assume continued expansion in revenue and earnings, so recurring expense volatility or weak cash conversion would make that path harder to support.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. So what we will do as we near the launch and we gear up for it early in next year we will be sharing more about specifically what our expectations are around that and how we feel like we will be able to deliver on it and report out on it as we move forward.

    Cristin Hubbard ·

  2. It can take many months for a patient to titrate to a maintenance dose, so we expect the adolescent revenue contribution to build into 2027 and beyond.

    Cristin Hubbard ·

2 more statements are quoted under Upcoming events

What the records here don't tell us

  • The newest quarter held here (Q3 FY2025) was filed Oct 28, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does BioMarin Pharmaceutical compare with its peers?

Short answer

BioMarin Pharmaceutical's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

BioMarin sits between a development-stage biotechnology company and a broad pharmaceutical manufacturer. It has multiple marketed rare-disease therapies, specialized distribution channels and substantial product revenue, yet its portfolio remains concentrated in small patient populations where diagnosis, treatment initiation, titration and purchasing schedules can materially affect sales timing.

Compared with pipeline-led peers, existing products provide revenue, gross profit and operating cash flow that can finance development work. Compared with diversified drugmakers, BioMarin retains greater exposure to individual rare-disease franchises and to the research and commercialization demands surrounding them.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Named competitor$68.29 Nov 18, 2026$16.7B98 5-pillar Nov 18, 2026
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$95.05 Nov 18, 2026$7.47B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.34 Nov 18, 2026$9.34B96 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$95.80 Nov 18, 2026$10.9B95 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.75 Nov 18, 2026$11.4B92 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$67.79 Nov 18, 2026$7.42B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$66.12 Nov 18, 2026$9.99B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$127.16 Nov 18, 2026$8.30B88 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Named competitor$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Same industry, near in market value$149.40 Nov 18, 2026$20.0B72 5-pillar Nov 18, 2026
BioMarin Pharmaceutical (BMRN) — this page$61.43$11.9B58

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$59.00 – $122.00
Consensus target
$90.33
Median target
$90.00

Consensus record · Captured .

Measured against a quoted price of $61.43 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 30, 2026

Transactions
12
Identified insiders
12
Purchases
0
Sales
1
Other transactions
11

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
96.1% Period end Sep 30, 2026
Reporting holders
585 Period end Sep 30, 2026
Previous quarter · holders
588 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.20,735,548
Primecap Management Co/Ca/14,988,996
Dodge & Cox14,625,740
Vanguard Capital Management LLC8,723,746
Vanguard Portfolio Management LLC8,371,887

Tracked investors

Which of the 16 named investors we follow held BMRN in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Viking GlobalAndreas HalvorsenQ3 20261.32%$430.39MTrimmed −5.8% shares
Bridgewater AssociatesFounded by Ray DalioQ3 20260%$0Sold out (was $15.73M)

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about BioMarin Pharmaceutical (BMRN)?

Read these with our analysis →

What Investors Ask About BioMarin Pharmaceutical (BMRN) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

How do Galafold, Pombility and Opfolda change BioMarin's commercial profile?

They broaden the enzyme-therapy portfolio beyond BioMarin's historical products. Management expected fuller contributions from these medicines to support stronger later-period revenue, making their commercial uptake important to the growth narrative.

Why can Palynziq sales move differently from patient starts?

Purchasing and stocking can shift revenue between reporting periods, while newly treated patients must progress toward maintenance dosing. Patient growth may therefore precede its full effect on reported sales.

What makes Voxzogo different from BioMarin's enzyme therapies?

Voxzogo is a daily injectable therapy for achondroplasia, whereas products such as Vimizim and Naglazyme replace enzymes for specific metabolic disorders. They share specialized rare-disease channels but address different conditions through different treatment mechanisms.

Does BioMarin rely mainly on its gene-therapy pipeline?

Marketed medicines already produce nearly all company revenue, so the business is not chiefly dependent on pipeline assets for current sales. Gene-therapy programs add development potential alongside an established commercial portfolio.

What is the BMRN stock price today?

The last price recorded for BioMarin Pharmaceutical Inc. (BMRN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BMRN price target?

The analyst consensus price target for BioMarin Pharmaceutical Inc. (BMRN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 80 figures on this page — 1 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands); Cash and short-term investments over time (USD millions); Management outlook — dated call excerpts
  • 1. What is BioMarin Pharmaceutical (BMRN), and what does it report?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Management outlook — dated call excerpts
  • 2. What do the latest results show for BioMarin Pharmaceutical (BMRN)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Most recent periodic reports
  • 3. What are the financial strengths and risks for BioMarin Pharmaceutical (BMRN)?: Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Distress and quality screens; Revenue by segment; Management outlook — dated call excerpts
  • 4. What should you watch next at BioMarin Pharmaceutical (BMRN)?: Management outlook — dated call excerpts; Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions)
  • 5. How does BioMarin Pharmaceutical compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • FAQ: How do Galafold, Pombility and Opfolda change BioMarin's commercial profile?: Management outlook — dated call excerpts; Recent SEC filings
  • FAQ: Why can Palynziq sales move differently from patient starts?: Management outlook — dated call excerpts; Business description
  • FAQ: What makes Voxzogo different from BioMarin's enzyme therapies?: Business description
  • FAQ: Does BioMarin rely mainly on its gene-therapy pipeline?: Business description; Revenue by segment; Annual revenue and net result (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold BMRN

Funds in our ETF coverage that list BMRN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Global X - Genomics & Biotechnology ETF (GNOM)4.31%
Alger Russell Innovation ETF (INVN)2.52%